TNBC tumors recurrence following treatment with PARP-inhibitors can be explained by recent studies demonstrating that PARP-inhibitors eliminate the bulk of tumor cells, but they have limited ability to eliminate CD44+/CD24− CSCs (38). This evidence concerns the gene PARP1 and neoplasm.